[ 18 F]FDG PET may differentiate cerebral amyloid angiopathy from Alzheimer’s disease

2021 ◽  
Author(s):  
Sébastien Bergeret ◽  
Mathieu Queneau ◽  
Mathieu Rodallec ◽  
Emmanuel Curis ◽  
Julien Dumurgier ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebral Amyloid Angiopathy ◽  
Fdg Pet ◽  
Amyloid Angiopathy ◽  
Cerebral Amyloid

Abstract P418: Stroke Admissions and Outcomes Among Cerebral Amyloid Angiopathy and Alzheimer’s Disease in the National Inpatient Sample

Stroke ◽  
2021 ◽  
Vol 52 (Suppl_1) ◽  
Author(s):  
Nandakumar Nagaraja ◽  
Urvish K Patel
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Hospital Mortality ◽  
Cerebral Amyloid Angiopathy ◽  
Amyloid Angiopathy ◽  
Secondary Diagnosis ◽  
National Inpatient Sample ◽  
Admission Rates ◽  
Secondary Outcomes ◽  
Cerebral Amyloid

Background/Purpose: Although cerebral amyloid angiopathy (CAA) and Alzheimer’s Disease (AD) can manifest as separate diseases it can co-exist due to shared amyloid β pathogenic mechanisms. We assessed admission rates and outcomes of ischemic stroke (IS), intracerebral hemorrhage (ICH), and subarachnoid hemorrhage (SAH) among hospitalized patients with a secondary diagnosis of AD and CAA. Methods: Adult patients discharged with a secondary diagnosis of CAA or AD in National Inpatient Sample (NIS) in the years 2016 and 2017 were identified. Admission rates for IS, ICH, and SAH were primary outcomes. In-hospital mortality and discharge to home were secondary outcomes. Multivariate logistic regression analysis was performed to evaluate secondary outcomes with model adjusted for demographics, medical history, hospital characteristics, and Elixhauser comorbidity index. Results: Among 60,609,519 admissions in NIS, 893,834 (1.5%) patients had a secondary diagnosis of AD [mean age 82.1 years and 62% women] and 14,850 (0.02%) patients had CAA [mean age 76.2 years and 51% women]. Combined AD+CAA was present in 1,335 (0.002%) patients. Compared to AD and controls (non AD or CAA), patients with CAA had higher admission rates for IS (11.5% CAA vs 2.8% AD vs 1.7% control, p<0.0001), for ICH (29.5% CAA vs 0.4% AD vs 0.2% control, p<0.0001) and for SAH (3% CAA vs 0.1% AD vs 0.1% control, p<0.0001). Among patients admitted for IS, discharge to home was less likely in AD compared to controls (10.4% AD vs 36.3% control, OR=0.40; 95%CI=0.36-0.44). Among patients admitted for ICH, discharge to home was less likely in AD compared to controls (6.3% AD vs 18.5% control, OR=0.57; 95%CI=0.41-0.78) but higher in CAA (17.8% CAA vs 18.5% control, OR=1.35; 95%CI=1.11-1.63). In-hospital mortality was less likely in patients with CAA than controls among patients admitted for ICH (9.6% CAA vs 23% control, OR=0.33; 95%CI=0.26-0.41) and SAH (6.7% CAA vs 19.1% control, OR=0.27; 95%CI=0.11-0.62). Conclusion: Admissions for IS, ICH, and SAH were higher among CAA compared to AD in NIS. CAA patients had lower in-hospital mortality for ICH and SAH admissions and higher rates of home discharge for ICH admissions. AD patients were less likely to be discharged home for IS and ICH admissions.

scholarly journals Effect of Cerebral Amyloid Angiopathy on Brain Iron, Copper, and Zinc in Alzheimer's Disease

2011 ◽  
Vol 24 (1) ◽  
pp. 137-149 ◽  
Author(s):  
Matthew Schrag ◽  
Andrew Crofton ◽  
Matthew Zabel ◽  
Arshad Jiffry ◽  
David Kirsch ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebral Amyloid Angiopathy ◽  
Amyloid Angiopathy ◽  
Brain Iron ◽  
Iron Copper ◽  
Copper And Zinc ◽  
Cerebral Amyloid

scholarly journals Proteomics analysis identifies new markers associated with capillary cerebral amyloid angiopathy in Alzheimer’s disease

2018 ◽  
Vol 6 (1) ◽  
Author(s):  
David C. Hondius ◽  
Kristel N. Eigenhuis ◽  
Tjado H. J. Morrema ◽  
Roel C. van der Schors ◽  
Pim van Nierop ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebral Amyloid Angiopathy ◽  
Amyloid Angiopathy ◽  
Proteomics Analysis ◽  
Cerebral Amyloid

scholarly journals Taxifolin is a novel therapeutic agent for Alzheimer’s disease and cerebral amyloid angiopathy

2020 ◽  
Vol 16 (S9) ◽  
Author(s):  
Satoshi Saito ◽  
Masashi Tanaka ◽  
Noriko Satoh‐Asahara ◽  
Roxana O. Carare ◽  
Roy O. Weller ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebral Amyloid Angiopathy ◽  
Therapeutic Agent ◽  
Amyloid Angiopathy ◽  
Cerebral Amyloid ◽  
Novel Therapeutic
Sign in / Sign up

Export Citation Format

Share Document